share_log

DEF 14A: Definitive information statements

DEF 14A: Definitive information statements

DEF 14A:股東委託書決議
美股SEC公告 ·  10/05 04:20

牛牛AI助理已提取核心訊息

Cardio Diagnostics Holdings, Inc. (Cardio Diagnostics) has announced an upcoming annual meeting of stockholders scheduled for November 15, 2024. The meeting will be entirely virtual, allowing stockholders to attend, vote, and submit questions during the live webcast. The Notice of Annual Meeting of Stockholders and Proxy Statement details the admission process and the business to be conducted, which includes the election of seven board nominees, approval of a reverse stock split, approval of future issuance of shares, and ratification of the company's independent registered public accounting firm for the fiscal year ended December 31, 2023. Stockholders are encouraged to vote promptly, with options to vote by proxy card or via the Internet. The meeting's agenda also addresses a proposal for the future...Show More
Cardio Diagnostics Holdings, Inc. (Cardio Diagnostics) has announced an upcoming annual meeting of stockholders scheduled for November 15, 2024. The meeting will be entirely virtual, allowing stockholders to attend, vote, and submit questions during the live webcast. The Notice of Annual Meeting of Stockholders and Proxy Statement details the admission process and the business to be conducted, which includes the election of seven board nominees, approval of a reverse stock split, approval of future issuance of shares, and ratification of the company's independent registered public accounting firm for the fiscal year ended December 31, 2023. Stockholders are encouraged to vote promptly, with options to vote by proxy card or via the Internet. The meeting's agenda also addresses a proposal for the future issuance of shares equal to 20% or more of the outstanding common stock in a non-public transaction, subject to Nasdaq Marketplace Listing Rule 5635(d). Additionally, the ratification of Prager Metis CPA's LLC as the company's auditor for the upcoming fiscal year is proposed. The event emphasizes the importance of stockholder participation in the decision-making process of the company.
心臟診斷控股公司(Cardio Diagnostics)宣佈將於2024年11月15日舉行股東年度大會。 會議將完全以虛擬形式進行,股東可以通過直播網絡會議參加、投票並提交問題。 關於股東年度大會通知和代理聲明詳細說明了入場流程和將要進行的業務,包括選舉七名董事提名人、批准股票逆向拆分、批准未來發行股票以及覈准截至2023年12月31日的財政年度公司獨立註冊會計師。 鼓勵股東及時投票,可選擇通過代理卡或互聯網進行投票。 會議議程還涉及一項提案,即在非公開交易中發行的股份佔已發行普通股20%或更多,受納斯達克市場上市規則5635(d)約束。此外,還建議批准Prager Metis CPA's LLC作爲公司未來一個財政年度的核數師。 此次活動強調了股東在公司決策過程中的參與的重要性。
心臟診斷控股公司(Cardio Diagnostics)宣佈將於2024年11月15日舉行股東年度大會。 會議將完全以虛擬形式進行,股東可以通過直播網絡會議參加、投票並提交問題。 關於股東年度大會通知和代理聲明詳細說明了入場流程和將要進行的業務,包括選舉七名董事提名人、批准股票逆向拆分、批准未來發行股票以及覈准截至2023年12月31日的財政年度公司獨立註冊會計師。 鼓勵股東及時投票,可選擇通過代理卡或互聯網進行投票。 會議議程還涉及一項提案,即在非公開交易中發行的股份佔已發行普通股20%或更多,受納斯達克市場上市規則5635(d)約束。此外,還建議批准Prager Metis CPA's LLC作爲公司未來一個財政年度的核數師。 此次活動強調了股東在公司決策過程中的參與的重要性。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。